vs
FENNEC PHARMACEUTICALS INC.（FENC）与TRANSACT TECHNOLOGIES INC（TACT）财务数据对比。点击上方公司名可切换其他公司
FENNEC PHARMACEUTICALS INC.的季度营收约是TRANSACT TECHNOLOGIES INC的1.2倍（$13.8M vs $11.5M），FENNEC PHARMACEUTICALS INC.同比增速更快（73.8% vs 11.9%），过去两年TRANSACT TECHNOLOGIES INC的营收复合增速更高（3.5% vs -26.3%）
Fennec制药是一家生物制药企业，专注于开发和商业化可降低儿童癌症患者治疗相关副作用的特种疗法，核心产品针对化疗引发的耳毒性，主要市场覆盖北美，服务肿瘤诊疗机构及儿童肿瘤患者群体。
该公司相关归属主体罗珀技术公司是一家控股集团，主要投资控股科技领域的各类企业，业务覆盖多个科技细分赛道，依托旗下子公司开展多元化科技业务布局。
FENC vs TACT — 直观对比
营收规模更大
FENC
是对方的1.2倍
$11.5M
营收增速更快
FENC
高出61.9%
11.9%
两年增速更快
TACT
近两年复合增速
-26.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.8M | $11.5M |
| 净利润 | $-4.8M | — |
| 毛利率 | — | 47.6% |
| 营业利润率 | -18.5% | -10.1% |
| 净利率 | -34.7% | — |
| 营收同比 | 73.8% | 11.9% |
| 净利润同比 | -141.1% | — |
| 每股收益（稀释后） | $-0.17 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FENCTACT
| Q4 25 | $13.8M | $11.5M | ||
| Q3 25 | $12.5M | $13.2M | ||
| Q2 25 | $9.7M | $13.8M | ||
| Q1 25 | $8.8M | $13.1M | ||
| Q4 24 | $7.9M | $10.2M | ||
| Q3 24 | $7.0M | $10.9M | ||
| Q2 24 | $7.3M | $11.6M | ||
| Q1 24 | $25.4M | $10.7M |
净利润FENCTACT
| Q4 25 | $-4.8M | — | ||
| Q3 25 | $-638.0K | $15.0K | ||
| Q2 25 | $-3.2M | $-143.0K | ||
| Q1 25 | $-1.2M | $19.0K | ||
| Q4 24 | $-2.0M | — | ||
| Q3 24 | $-5.7M | $-551.0K | ||
| Q2 24 | $-5.6M | $-319.0K | ||
| Q1 24 | $12.8M | $-1.0M |
毛利率FENCTACT
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
营业利润率FENCTACT
| Q4 25 | -18.5% | -10.1% | ||
| Q3 25 | -1.5% | 0.1% | ||
| Q2 25 | -28.3% | -1.9% | ||
| Q1 25 | -9.2% | -0.1% | ||
| Q4 24 | -11.8% | -10.3% | ||
| Q3 24 | -74.6% | -7.7% | ||
| Q2 24 | -69.4% | -3.8% | ||
| Q1 24 | 54.2% | -12.2% |
净利率FENCTACT
| Q4 25 | -34.7% | — | ||
| Q3 25 | -5.1% | 0.1% | ||
| Q2 25 | -32.7% | -1.0% | ||
| Q1 25 | -13.3% | 0.1% | ||
| Q4 24 | -25.0% | — | ||
| Q3 24 | -82.2% | -5.1% | ||
| Q2 24 | -76.5% | -2.8% | ||
| Q1 24 | 50.6% | -9.7% |
每股收益（稀释后）FENCTACT
| Q4 25 | $-0.17 | $-0.11 | ||
| Q3 25 | $-0.02 | $0.00 | ||
| Q2 25 | $-0.11 | $-0.01 | ||
| Q1 25 | $-0.04 | $0.00 | ||
| Q4 24 | $-0.02 | $-0.80 | ||
| Q3 24 | $-0.21 | $-0.06 | ||
| Q2 24 | $-0.20 | $-0.03 | ||
| Q1 24 | $0.41 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $36.8M | $20.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $35.5M | $31.1M |
| 总资产 | $70.6M | $44.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FENCTACT
| Q4 25 | $36.8M | $20.4M | ||
| Q3 25 | $21.9M | $20.0M | ||
| Q2 25 | $18.7M | $17.7M | ||
| Q1 25 | $22.7M | $14.2M | ||
| Q4 24 | $26.6M | $14.4M | ||
| Q3 24 | $40.3M | $11.3M | ||
| Q2 24 | $43.1M | $11.1M | ||
| Q1 24 | $51.2M | $10.6M |
总债务FENCTACT
| Q4 25 | — | — | ||
| Q3 25 | $19.4M | — | ||
| Q2 25 | $19.4M | — | ||
| Q1 25 | $19.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | $32.1M | — | ||
| Q2 24 | $31.8M | — | ||
| Q1 24 | $31.3M | — |
股东权益FENCTACT
| Q4 25 | $35.5M | $31.1M | ||
| Q3 25 | $-4.5M | $31.8M | ||
| Q2 25 | $-7.5M | $31.3M | ||
| Q1 25 | $-5.9M | $30.9M | ||
| Q4 24 | $-5.9M | $30.6M | ||
| Q3 24 | $-5.2M | $38.4M | ||
| Q2 24 | $-1.4M | $38.5M | ||
| Q1 24 | $3.0M | $38.6M |
总资产FENCTACT
| Q4 25 | $70.6M | $44.8M | ||
| Q3 25 | $49.3M | $45.0M | ||
| Q2 25 | $44.9M | $44.5M | ||
| Q1 25 | $46.4M | $44.2M | ||
| Q4 24 | $44.9M | $44.0M | ||
| Q3 24 | $58.9M | $50.5M | ||
| Q2 24 | $63.2M | $50.4M | ||
| Q1 24 | $69.2M | $51.9M |
负债/权益比FENCTACT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 10.40× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.0M | $609.0K |
| 自由现金流经营现金流 - 资本支出 | — | $589.0K |
| 自由现金流率自由现金流/营收 | — | 5.1% |
| 资本支出强度资本支出/营收 | — | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $7.6M |
8季度趋势，按日历期对齐
经营现金流FENCTACT
| Q4 25 | $-6.0M | $609.0K | ||
| Q3 25 | $1.5M | $3.6M | ||
| Q2 25 | $-3.7M | $3.6M | ||
| Q1 25 | $-4.3M | $-161.0K | ||
| Q4 24 | $-1.5M | $2.4M | ||
| Q3 24 | $-2.2M | $327.0K | ||
| Q2 24 | $-8.4M | $636.0K | ||
| Q1 24 | $39.0M | $-1.5M |
自由现金流FENCTACT
| Q4 25 | — | $589.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $-171.0K | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | — | $259.0K | ||
| Q2 24 | — | $499.0K | ||
| Q1 24 | — | $-1.6M |
自由现金流率FENCTACT
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | — | 25.9% | ||
| Q1 25 | — | -1.3% | ||
| Q4 24 | — | 23.2% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | -14.9% |
资本支出强度FENCTACT
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | 1.0% |
现金转化率FENCTACT
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.04× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
